CADASIL: The most common hereditary subcortical vascular dementia

Future Neurology

Volumn 3, Issue 6, 2008, Pages 683-704

  Kalimo, Hannu ^a,b,c   Miao, Qing ^d   Tikka, Saara ^e   Mykkänen, Kati ^d   Junna, Maija ^d   Roine, Susanna ^c   Viltanen, Matti ^d,f   Pöyhönen, Minna ^a,e   Baumann, Marc ^e  

^a HELSINKI UNIVERSITY CENTRAL HOSPITAL   (Finland)

^b UPPSALA UNIVERSITY   (Sweden)

^c TURKU UNIVERSITY HOSPITAL   (Finland)

^d UNIVERSITY OF TURKU   (Finland)

^e UNIVERSITY OF HELSINKI   (Finland)

^f KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

CADASIL; Granular osmiophilic material; Hereditary vascular dementia; Leukoaraiosis; Migraine; Notch3; Small vessel disease; Stroke

Indexed keywords

ANTICOAGULANT AGENT; ANTIHYPERTENSIVE AGENT; ARGININE; CHOLINESTERASE INHIBITOR; CYSTEINE; DONEPEZIL; ERGOTAMINE DERIVATIVE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; MEMBRANE RECEPTOR; NEUROLEPTIC AGENT; NOTCH3 RECEPTOR; PLACEBO; PLATELET DERIVED GROWTH FACTOR RECEPTOR; TRICYCLIC ANTIDEPRESSANT AGENT; TRIPTAN DERIVATIVE;

BRAIN DISEASE; BRAIN HEMORRHAGE; BRAIN VASOSPASM; CADASIL; CEREBROVASCULAR ACCIDENT; CLINICAL FEATURE; CLINICAL TRIAL; COGNITIVE DEFECT; CORONARY ARTERY DISEASE; DEMENTIA; DIFFERENTIAL DIAGNOSIS; ELECTRON MICROSCOPY; ENDOCYTOSIS; GENETIC CODE; GENETIC DISORDER; GENETIC LINKAGE; GRAY MATTER; HISTOPATHOLOGY; HUMAN; HYPERCHOLESTEROLEMIA; INCIDENCE; MELAS SYNDROME; MEMORY DISORDER; MIGRAINE WITH AURA; MISSENSE MUTATION; MOLECULAR MECHANICS; MOOD DISORDER; MULTIINFARCT DEMENTIA; MUTATIONAL ANALYSIS; NEUROPATHOLOGY; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; PREVALENCE; PRIORITY JOURNAL; PROTEIN FOLDING; REGULATORY MECHANISM; REVIEW; SIGNAL TRANSDUCTION; TRANSIENT ISCHEMIC ATTACK; WHITE MATTER;

EID: 67149088447     PISSN: 14796708     EISSN: None     Source Type: Journal    
DOI: 10.2217/14796708.3.6.683     Document Type: Review

References (139)

1. Joutel A, Corpechot C, Ducros A et al.: Notch3 mutations in CADASIL, a hereditary late-onset condition causing stroke and dementia. Nature 383, 707-710 (1996).
2. Tikka S, Mykkänen K, Ruchoux M-M et al.: Congruence between NOTCH3 mutations and GOM in 131 CADASIL patients. (2008) (In Press).
3. van Bogaert L: Encephalopathie souscorticale progressive (Binswanger) a evolution rapide chez deuz soeurs. Med. Hellen 24, 961-972 (1955).
4. Sourander P, Wålinder J: Hereditary multi-infarct dementia. Morphological and clinical studies of a new disease. Acta Natropathol. 39, 247-254 (1977).
5. Low WC, Junna M, Börjesson-Hanson A et al.: Hereditary multi-infarct dementia of the Swedish type is a novel disorder different from NOTCH 3 causing CADASIL. Brain 130, 357-367 (2007).
6. Tournier-Lasserve E, Joutel A, Melki J et al.: Cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy maps to chromosome 19q12. Nat. Genet. 3, 256-259 (1933).
7. Joutel A, Vahedi K, Corpechot C et al.: Strong clustering and stereotyped nature of Notch3 mutations in CADASIL patients. Lancet 350, 1511-1515 (1997).
8. Markus HS, Martin RJ, Simpson MA et al.: Diagnostic strategies in CADASIL. Neurology 59, 1134-1138 (2002).
9. Razvi SS, Davidson R, Bone I, Muir KW: The prevalence of cerebral autosomal dominant arteriopathy with subcorrical infarcts and leucoencephalopathy (CADASIL) in the west of Scotland. J. Neurol. Neurosurg. Psychiatry 76, 739-741 (2005).
10. Dong Y, Hassan A, Zhang Z, Huber D, Dalageorgou C, Markus HS: Yield of screening for CADASIL mutations in lacunar stroke and leukoaraiosis. Stroke 34, 203-205 (2003).
11. Markus HS, Martin RJ, Simpson MA et al.: Diagnostic strategies in CADASIL. Neurology 59, 1134-1138 (2002).
12. Chabriat H, Vahedi K, Iba-Zizen MT et al.: Clinical spectrum of CADASIL: a study of 7 families. Cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy. Lancet 346, 934-939 (1995).
13. Dichgans M, Mayer M, Uttner I et al.: The phenotypic spectrum of CADASIL: Clinical findings in 102 cases. Ann. Neurol. 44, 731-739 (1998).
14. Kalimo H and Kalaria RN: Hereditary forms of vascular dementias. In: Pathology and Genetics: Cerebrovascular Diseases. Kalimo H (Ed). Chapter 41. ISN Neuropath Press, Basel, 324-334 (2005).
15. Mykkänen K, Junna M, Amberla K et al.: Different clinical phenotypes in monozygotic CADASIL twins with a novel NOTCH3 mutation. (2008) (In Press).
16. Singhal S, Bevan S, Barrick T, Rich P, Markus HS: The influence of genetic and cardiovascular risk factors on the CADASIL phenotype. Brain 127, 2031-2038 (2004).
17. Opherk C, Peters N, Herzog J, Luedtke R, Dichgans M: Long-term prognosis and causes of death in CADASIL: a retrospective studygn 411 patients. Brain 127, 2533-2539 (2004).
18. Arboleda-Velasquez JF, Lopera F, Lopez E et al.: C455R notch3 mutation in a Colombian CADASIL kindred with early onset of stroke. Neurology 59, 277-279 (2002).
19. Vahedi K, Chabriat H, Levy C, Joutel A, Tournier-Lasserve E, Bousser MG: Migraine with aura and brain magnetic resonance imaging abnormalities in patients with CADASIL. Arch. Neurol. 61, 1237-1240 (2004).
20. 2+ channel gene in familial hemiplegic migraine and migraine with and without aura. Headache 37, 479-485 (1997).
21. Roine S, Pöyhönen M, Timonen S et al.: Neurologic symptoms are common during gestation and puerperium in CADASIL. Neurology 64, 1441-1443 (2005).
22. Choi EJ, Choi CG, Kim JS: Medium to large cerebral artery involvement in CADASIL. Neurology 65, 1322-1324 (2005).
23. Miao, Q, Kalimo H, Bogdanovic N, Kostulas K, Börjesson-Hanson A, Viitanen M: Long penetrating cerebral arterioles are early affected in CADASIL. Neuropathol. Appl. Neurobiol. 32, 455-458 (2006).
24. Mellies JK, Baumer T, Muller JA et al.: SPECT study of a German CADASIL family. A phenotype with migraine and progressive dementia only. Neurology 50, 1715-1721 (1998).
25. Desmond DW, Moroney JT, Lynch T, Chan S, Chin SS, Mohr JP: The natural history of CADASIL: a pooled analysis of previously published cases. Stroke 30, 1230-1233 (1999).
26. Choi JC, Kang SY, Kang JH, Park JK: Intracerebral hemorrhages in CADASIL. Neurology 66, 1511-1516 (2006).
27. Viswanathan A, Guichard JP, Gschwendtner A et al.: Blood pressure and haemoglobin A1c are associated with microhaemorrhage in CADASIL: a two-centre cohort study. Brain 129, 2375-2383 (2006).
28. Kalimo H, Ruchoux MM, Viitanen M, Kalari RN: CADASIL: a common form of hereditary arteriopathy causing brain infarcts and dementia. Brain Pathol. 12, 371-384 (2002).
29. Amberla K, Waljas M, Tuominen S et al.: Insidious cognitive decline in CADASIL Stroke 35, 1598-1602. (2004).
30. Peters N, Opherk C, Danek A, Ballard C, Herzog J, Dichgans M: The pattern of cognitive performance in CADASIL: a monogenic condition leading to subcortical ischemic vascular dementia. Am. J. Psychiatry 162, 2078-2085 (2005).
31. Taillia H, Chabriat H, Kuetz A et al.: Cognitive alterations in non-demented CADASIL patients. Cerebrovasc. Dis. 8, 97-101 (1998).
32. Trojano L, Ragno M, Manca A, Caruso G: A kindred affected by cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy (CADASIL): a 2-year neuropsychological follow-up. J. Neurol. 245, 217-222 (1998).
33. Liem MK, van der Grond J, Haan J et al.: Lacunar infarcts are the main correlate with cognitive dysfunction in CADASIL. Stroke 38, 923-928 (2007).
34. Viswanathan A, Gschwendtner A, Guichard JP et al.: Lesions are independently associated with disability and cognitive impairment in CADASIL. Neurology 69, 172-179 (2007).
35. Verin M, Rolland Y, Landgraf F, Chabriat H et al.: New phenotype of the cerebral autosomal dominat arteriopathy mapped to chromosome 19: migraine as the prominent clinical feature. J. Neurol. Neurosurg. Psych. 59, 579-585 (1995).
36. Lågas PA, Juvonen V: Schizophrenia in a patient with cerebral autosomally dominant arteriopathy with subcortical infarcts and leucoencephalopathy (CADASIL disease). Nord. J. Psychiatry 55, 41-42, (2001).
37. Chabriat H, Bousser MG: Neuropsychiatric manifestations in CADASIL. Dialogues. Clin. Neurosci. 9, 199-208 (2007).
38. Valenti R, Poggesi A, Pescini F, Inzitari D, Pantoni L: Psychiatric disturbances in CADASIL: a brief review. Acta Neurol. Scand. DOI: 10.1111/j.1600-0404.2008.01015.x (2008).
39. Haan J, Lesnik Oberstein SA, Ferrari MD: Epilepsy in cerebral autosomal dominant arteriopathy with subcortical infarcts and leucoencephalopathy. Cerebrovasc. Dis. 24, 316-317 (2007).
40. Valko PO, Siccoli MM, Schiller A et al.: Nonconvulsive status epileptics causing focal neurological deficits in CADASIL. J. Neurol. Neurosurg. Psychiatry 78, 1287-1289 (2007).
41. Schon F, Martin RJ, Prevett M et al.: 'CADASIL coma': an underdiagnosed acute encephalopathy. J. Neurol. Neurosurg. Psychiatry 74, 249-252 (2003)
42. Sicurelli F, Dotti MT, De Stefano N et al.: Peripheral neuropathy in CADASIL. J. Neurol. 252, 1206-1209 (2005).
43. Lesnik Oberstein SA, Jukema JW, Van Duinen SG et al.: Myocardial infarction in cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy (CADASIL). Medicine (Baltimore) 82, 251-256 (2003).
44. Cumurciuc R, Henry P, Gobron C et al.: Electrocardiogram in cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy patients without any clinical evidence of coronary artery disease: a case-control study. Stroke 37, 1100-1102 (2006).
45. Rufa A, Guideri F, Acampa M et al.: Cardiac autonomic nervous system and risk of arrhythmias in cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy (CADASIL). Stroke 38, 276-280 (2007).
46. Finsterer J: Neuromuscular implications in CADASIL. Cerebrovasc. Dis. 24, 401-404 (2007).
47. Davous P: CADASIL: a review with proposed diagnostic criteria. Eur. J. Neurol. 5, 219-233 (1998).
48. Lesnik Oberstein SA, van den Boom R, Middelkoop HA et al.: Incipient CADASIL. Arch. Neurol. 60, 707-712 (2003).
49. Peters N, Herzog J, Opherk C, Dichgans M: A two-year clinical follow-up study in 80 CADASIL subjects: progression patterns and implications for clinical trials. Stroke 35, 1603-1608 (2004).
50. Junna M, Mykkänen K, Pescini F et al.: Genetic factors may modify the clinical course of CADASIL. (2008) (In Press).
51. Chabriat H, Levy C, Taillia H et al.: Patterns of MRI lesions in CADASIL. Neurology 51, 452-457 (1998).
52. Chabriat H, Pappata S, Poupon C et al.: Clinical severity in CADASIL related to ultrastructural damage in white matter: in vivo study with diffusion tensor MRI. Stroke 30, 2637-2643 (1999).
53. Lesnik Oberstein SA, van den Boom R, van Buchem MA et al.: The Dutch CADASIL Research Group: cerebral microbleeds in CADASIL. Neurology 57, 1066-1070 (2001).
54. Dichgans M, Holtmannspotter M, Herzog J, Peters N, Bergmann M, Yousry TA: Cerebral microbleeds in CADASIL: a gradient-echo magnetic resonance imaging and autopsy study. Stroke 33, 67-71 (2002).
55. Dichgans M, Petersen D: Angiographic complications in CADASIL. Lancet 549, 776-777 (1997).
56. Chabriat H, Bousser M-G, Pappata S: Cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy: a positron emission tomography study in two affected family members. Stroke 26, 1729-1730 (1995).
57. Tuominen S, Miao Q, Kurki T et al.: Positron emission tomography examination of cerebral blood flow and glucose metabolism in young CADASIL patients. Stroke 35, 1063-1067 (2004).
58. Chabriat H, Pappata S, Ostergaard L et al.: Cerebral hemodynamics in CADASIL before and after acetazolamide challenge assessed with MRI bolus tracking. Stroke 31, 1904-1912 (2000).
59. Bruening R, Dichgans M, Berchtenbreiter C et al.: Cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy: decrease in regional cerebral blood volume in hyperintense subcortical lesions inversely correlates with disability and cognitive performance. Am. J. Neuroradiol. 22, 1268-1274 (2001).
60. Liebetrau M, Herzog J, Kloss CU, Hamann GF, Dichgans M: Prolonged cerebral transit time in CADASIL: a transcranial ultrasound study. Stroke 33, 509-512 (2002).
61. Stenborg A, Kalimo H, Viitanen M, Terent A, Lind L: Impaired endothelial function of forearm resistance arteries in CADASIL patients. Stroke 38, 2692-2697 (2007).
62. Dubroca C, Lacombe P, Domenga V et al.: Impaired vascular mechanotransduction in a transgenic mouse model of CADASIL arteriopathy. Stroke 36, 113-117 (2005).
63. Baudrimont M, Dubas F, Joutel A, Tournier-Lasserve E, Bousser MG: Autosomal dominant leukoencephalopathy and subcortical ischemic stroke. A clinicopathological study. Stroke 24, 122-125 (1993).
64. Ruchoux MM, Guerouaou D, Vandenhaute B, Pruvo JP, Vermersch P, Leys D: Systemic vascular smooth muscle cell impairment in cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy. Acta Neuropathol. 89, 500-512 (1995).
65. Tuominen S, Juvonen V, Amberla K et al.: Phenotype of a homozygous CADASIL patient in comparison to 9 age-matched,; heterozygous patients with the same R133C Notch3 mutation. Stroke 32, 1767-1774 (2001).
66. Brulin P, Godfraind C, Leteurtre E, Ruchoux MM: Morphometric analysis of ultrastructural vascular changes in CADASIL: analysis of 50 skin biopsy specimens and pathogenic implications. Acta Neuropathol. 104, 241-248 (2002).
67. Ishiko A, Shimizu A, Nagata E, Takahashi K, Tabira T, Suzuki N: Notch3 ectodomain is a major component of granular osmiophilic material (GOM) in CADASIL. Acta Neuropathol. 112, 333-339 (2006).
68. Joutel A, Favrole P, Labauge P et al.: Skin biopsy immunostaining with a Notch3 monoclonal antibody for CADASIL diagnosis. Lancet 358, 2049-2051 (2001).
69. Miao Q, Paloneva T, Tuominen S et al.: Fibrosis and stenosis of the long penetrating cerebral arteries: the cause of the white matter pathology in cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy. Brain Pathol. 14, 358-364 (2004).
70. Miao Q, Paloneva T, Tuisku S et al.: Arterioles of the lenticular nucleus in CADASIL. Stroke 37, 2242-2247 (2006).
71. Arboleda-Velasquez JF, Zhou Z, Shin HK et al.: Linking Notch signaling to ischemic stroke. Proc. Natl Acad. Sci. USA 105, 4856-4861 (2008).
72. Ruchoux MM, Maurage CA: Endothelial changes in muscle and skin biopsies in patients with CADASIL. Neuropathol. Appl. Neurobiol. 24, 60-65 (1998).
73. Armulik A, Abramsson A, Betsholtz C: Endothelial/pericyte interactions. Circ. Res. 97, 512-523 (2005).
74. Domenga V, Fardoux P, Lacombe P et al.: Notch3 is required for arterial identity and maturation of vascular smooth muscle cells. Genes Dev. 18, 2730-2735 (2004).
75. Peters N, Freilinger T, Opherk C, Pfefferkorn T, Dichgans M: Enhanced L-arginine-induced vasoreactivity suggests endothelial dysfunction in CADASIL. J. Neurol. DOI: 10.1007/s00415-008-0876-9 (2008).
76. Joutel A, Dodick DD, Parisi JE, Cecillon M, Tournier-Lasserve E, Bousser MG: De novo mutation in the NOTCH3 gene causing CADASIL. Ann. Neurol. 47, 388-391 (2000).
77. Coto E, Menéndez M, Navarrro R, Garcia-Castro M, Alvarez V: A de novo Notch3 mutation causing CADASIL. Eur. J. Neurol. 13, 628-631 (2006).
78. Kotorii S, Takahashi K, Kamimura K et al.: Mutations of the NOTCH3 gene in non-Caucasian patients with suspected CADASIL syndrome. Dement. Geriatr. Cogn. Disord. 12, 185-193 (2001).
79. Santa Y, Uyama E, Chui DH et al.: Genetic, clinical and pathological studies of CADASIL in Japan: a partial contribution of Notch3 mutations and implications of smooth muscle cell degeneration for the pathogenesis. J. Neurol. Sci. 212, 79-84 (2003).
80. Fouillade C, Chabriat H, Riant F et al.: Activating NOTCH3 mutation in a patient with small-vessel-disease of the brain. Hum. Mutat. 29, 452-461 (2008).
81. Artavanis-Tsakonas S, Rand MD, Lake RJ: Notch signaling: cell fate control and signal integration in development. Science 284, 770-776 (1999).
82. Lasky JL, Wu H: Notch signaling, brain development, and human disease. Pediatr. Res. 57, 104-109 (2005).
83. Roca C, Adams RH: Regulation of vascular morphogenesis by Notch signaling. Genes Dev. 21, 2511-2524 (2007).
84. Hansson EM, Lendahl U, Chapman G: Notch signaling in development and disease. Semin. Cancer Biol. 14, 320-328 (2004).
85. Lardelli M, Williams R, Lendahl U: Notch-related genes in animal development. Int. J. Dev. Biol. 39, 769-80 (1995).
86. Gridley T. Notch signaling in vascular development and physiology. Development 134, 2709-2718 (2007).
87. Gray GE, Mann RS, Mitsiadis E et al.: Human ligands of the Notch receptor. Am. J. Pathol. 154, 785-94 (1999).
88. Shimizu K, Chiba S, Saito T, Kumano K, Hirai H: Physical interaction of Delta1, Jagged1, and Jagged2 with Notch1 and Notch3 receptors. Biochem. Biophys. Res. Commun. 276, 385-389 (2000).
89. Nichols JT, Miyamoto A, Olsen SL, D'Souza B, Yao C, Weinmaster G: DSL ligand endocytosis physically dissociates Notch1 heterodimers before activating proteolysis can occur. J. Cell Biol. 176, 445-458 (2007).
90. Parks AL, Klueg KM, Stout JR, Muskavitch MA: Ligand endocytosis drives receptor dissociation and activation in the Notch pathway. Development 127, 1373-1385 (2000).
91. Blaumueller CM, Qi H, Zagouras P, Artavanis-Tsakonas S: Intracellular cleavage of Notch leads to a heterodimeric receptor on the plasma membrane. Cell 90, 281-291 (1997).
92. Brou C, Logeat F, Gupta N et al.: A novel proteolytic cleavage involved in Notch signaling: the role of the disintegrin-metalloprotease TACE. Mol. Cell 5, 207-216 (2000).
93. Mumm JS, Schroeter EH, Saxena MT et al.: A ligand-induced extracellular cleavage regulates γ-secretase-like proteolytic activation of Notch1. Mol. Cell 5, 197-206 (2000).
94. Chyung JH, Raper DM, Selkoe DJ: γ-secretase exists on the plasma membrane as an intact complex that accepts substrates and effects intramembrane cleavage. J. Biol. Chem. 280, 4383-4392 (2005).
95. Joutel A, Andreux F, Gaulis S et al.: The ectodomain of the Notch3 receptor accumulates within the cerebrovasculature of CADASIL patients. J. Clin. Invest. 105, 597-605 (2000).
96. Prakash N, Hansson E, Betsholtz C, Mitsiadis T, Lendahl U: Mouse Notch 3 expression in the pre- and postnatal brain: relationship to the stroke and dementia syndrome CADASIL. Exp. Cell Res. 278, 31-44 (2002).
97. Wang W, Struhl G: Drosophila epsin mediates. a select endocytic pathway that DSL ligands must enter to activate Notch. Development 131, 5367-5380 (2004).
98. Wang W, Struhl G: Distinct roles for mind bomb, neuralized and epsin in mediating DSL endocytosis and signaling in Drosophila. Development 132, 2883-2894 (2005).
99. Dichgans M: Monogenic causes of ischemic stroke. In: Stroke Genetics. H Markus (Ed.). Oxford University Press, NY, USA 127-163 (2003).
100. Joutel A, Monet M, Domenga V, Riant F, Tournier-Lasserve E: Pathogenic mutations associated with cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy differently affect Jagged1 binding and Notch3 activity via the RBP/JK signaling pathway. Am. J. Hum. Genet. 74, 338-347 (2004).
101. Peters N, Opherk C, Zacherle S, Capell A, Gempel P, Dichgans M: CADASIL-associated Notch3 mutations have differential effects both on ligand binding and ligand-induced Notch3 receptor signaling through RBP-Jk. Exp. Cell Res. 299, 454-464 (2004).
102. Krebs LT, Xue Y, Norton CR et al.: Characterization of Notch3-deficient mice: normal embryonic development and absence of genetic interactions with Notch 1 mutation. Genesis 37, 139-143 (2003).
103. Monet M, Domenga V, Lemaire B et al.: The archetypal R90C CADASIL-NOTCH3 mutation retains NOTCH3 function in vivo. Hum. Mol. Genet. 16, 982-992 (2007).
104. Jin S, Hansson EM, Tikka S et al.: Notch signaling regulates platelet-derived growth factor receptor-β expression in vascular smooth muscle cells. Circ. Res. 102, 1483-1491 (2008).
105. Hu QP, Ang BT, Karsak M et al.: F3/contactin acts as a functional ligand for Notch during oligodendrocyte maturation. Cell 115, 163-175 (2003).
106. Martinez Arias A, Zecchini V, Brennan K et al.: CSL-independent Notch signalling: a checkpoint in cell fate decisions during development? Curr. Opin. Genet. Dev. 12, 524-533 (2002).
107. Arboleda-Velasquez J, Rampal R, Fung E et al.: CADASIL mutations impair Notch3 glycosylation by Fringe. Hum. Mol. Genet. 14, 1631-1649 (2005).
108. Sayeed A, Ng DT: Search and destroy: ER quality control and ER-associated protein degradation. Crit. Rev. Biochem. Mol. Biol. 40, 75-91 (2005).
109. Karlström H, Beatus P, Dennaeus K, Chapman G, Lendahl U, Lundqvist J: A CADASIL mutated receptor exhibits impaired intracellular trafficking and maturation but normal ligand-induced signiling. Proc. Natl Acad. Sci. USA 99, 17119-17124 (2002).
110. Ihalainen S, Soliymani R, Iivanainen E et al.: Proteome analysis of cultivated vascular smooth muscle cells from a CADASIL patient. Mol. Med. 13, 305-314 (2007).
111. Spinner NB: CADASIL: Notch signaling defect or protein accumulation problem? J. Clin. Invest. 105, 561-562 (2000).
112. Wang W, Prince CZ, Mou Y, Pollman MJ: Notch3 signaling in vascular mooth muscle cells induces c-FLIP expression via ERK/MAPK activation. Resistance to Fas ligand-induced apoptosis. J. Biol. Chem. 277, 21723-21729 (2002).
113. Wang W, Prince CZ, Hu X, Pollman MJ: HRT1 modulates vascular smooth muscle cell proliferation and apoptosis. Biochem. Biophys. Res. Commun. 308, 596-601 (2003).
114. Sweeney C, Morrow D, Birney YA et al. Notch 1 and 3 receptor signaling modulates vascular smooth muscle cell growth, apoptosis, and migration via a CBF-1/RBP-Jk dependent pathway. FASEB J. 18, 1421-1423 (2004).
115. Noseda M, Fu Y, Niessen K et al.: Smooth Muscle α-actin is a direct target of Notch/CSL. Circ. Res. 98, 1468-1470 (2006).
116. Betsholtz C: Insight into the physiological functions of PDGF through genetic studies in mice. Cytokine Growth Factor Rev. 15, 215-228 (2004).
117. Marmur JD, Poon M, Rossikhina M, Taubman MB: Induction of PDGF-responsive genes in vascular smooth muscle. Implications for the early response to vessel injury. Circulation 86, 53-60 (1992).
118. Campos AH, Wang W, Pollman MJ, Gibbons GH: Determinants of Notch-3 receptor expression and signaling in vascular smooth muscle cells: implications in cell-cycle regulation. Circ. Res. 91, 999-1006 (2002).
119. Wang W, Campos AH, Prince CZ, Mou Y, Pollman MJ: Coordinate Notch3-hairy-related transcription factor pathway, regulation in response to arterial injury. Mediator role of platelet-derived growth factor and ERK. J. Biol. Chem. 277, 23165-23171 (2002).
120. Heistad DD: What's new in the cerebral microcirculation? Landis award lecture. Microcirculation. 8, 365-375 (2001).
121. Ruchoux MM, Domenga V, Brulin P et al.: Transgenic mice expressing mutant Notch3 develop vascular alterations characteristic of cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy. Am. J. Pathol. 162, 329-342 (2003).
122. Lacombe P, Oligo C, Domenga V, Tournier-Lasserve E, Joutel A: Impaired Cerebral vasoreactivity in a transgenic mouse model of cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy arteriopathy. Stroke 36, 1053-1058 (2005).
123. 2 reactivity in CADASIL: a transcranial Doppler sonography study. Stroke 32, 17-21 (2001).
124. Roine S, Harju M, Kivelä T et al.: Ophthalmologic findings in cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy (CADASIL). A cross-sectional study. Ophthalmology 113, 1411-1417 (2006).
125. Lundkvist J, Zhu S, Hansson E et al.: Mice carrying a R142C Notch 3 knock-in mutation do not develop a CADASIL-like phenotype. Genesis 41, 13-22 (2004).
126. Wessman M, Kallela M, Kaunisto MA et al.: A susceptibility locus for migraine with aura, on chromosome 4q24. Am. J. Hum. Genet. 70, 652-662 (2002).
127. Mykkänen K, Savontaus ML, Juvonen V et al.: Detection of the founder effect in Finnish CADASIL families. Eur. J. Hum. Genet. 12, 813-819 (2004).
128. Inzitari D, Sarti C: Screening for CADASIL mutations. Stroke 34, 205-206 (2003).
129. Schröder JM, Sellhaus B, Jorg J: Identification of the characteristic vascular changes in a sural biopsy of a case with cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy (CADASIL). Acta Neuropathol. 89, 116-121 (1995).
130. Tzourio C, Tehindrazanarivelo A, Iglésias S et al.: Case - control study of migraine and risk of ischaemic stroke in young women. Br. Med. J. 310, 830-833 (1995).
131. Majamaa K, Turkka J, Kärppä M, Winqvist S, Hassinen IE: The common MELAS mutation A3243G in mitochondrial DNA among young patients with an occipital brain infarct. Neurology 49, 1331-1334 (1997).
132. Annunen-Rasila J, Finnilä S, Mykkänen K et al.: Mitochondrial DNA sequence variation and mutation rate in patients with CADASIL. Neurogenetics 7, 185-194 (2006); erratum in: Neurogenetics 7, 281 (2006).
133. Forteza AM, Brozman B, Rabinstein AA, Romano JG, Bradley WG: Acetazolamide for the treatment of migraine with aura in CADASIL. Neurology 57, 2144-2145 (2001).
134. Nassief A, Marsh JD: Statin therapy for stroke prevention. Stroke 39, 1042-1048 (2008).
135. Peters N, Freilinger T, Opherk C, Pfefferkorn T, Dichgans M: Effects of short term atorvastatin treatment on cerebral hemodynamics in CADASIL. J. Neurol. Sci 260, 100-105 (2007).
136. Mesulam M, Siddique T, Cohen B: Cholinergic denervation in a pure multi-infarct state: observations on CADASIL. Neurology 60, 1183-1185 (2003).
137. Keverne JS, Low WC, Ziabreva I, Court JA, Oakley AE, Kalaria RN: Cholinergic neuronal deficits in CADASIL. Stroke 38, 188-191 (2007).
138. Manganelli F, Ragno M, Cacchiò G et al.: Motor cortex cholinergic dysfunction in CADASIL: a transcranial magnetic demonstration. Clin. Neurophysiol. 119, 351-355 (2008).
139. Dichgans M, Markus HS, Salloway S et al.: Donepezil in patients with subcortical vascular cognitive impairment: a randomised double-blind trial in CADASIL. Lancet Neurol. 7, 310-318 (2008).